Search Result

Isoforms Recommended:	Yes

Results for "

Yes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	YAP (6) Akt (1) Apoptosis (1) Aurora Kinase (1) Autophagy (2) Bcr-Abl (2) Btk (1) c-Fms (1) CDK (1) Checkpoint Kinase (Chk) (1) DNA/RNA Synthesis (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Ephrin Receptor (1) Estrogen Receptor/ERR (2) FAK (1) FGFR (6) FLT3 (1) HSP (2) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (1) LPL Receptor (2) MAP3K (1) PDGFR (4) PROTACs (1) Reference Standards (3) RET (1) Ribosomal S6 Kinase (RSK) (1) Small Interfering RNA (siRNA) (3) Src (17) VEGFR (5)
By Research Areas:	Cancer (24) Cardiovascular Disease (1) Endocrinology (2) Inflammation/Immunology (2) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: YAP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135299

CH6953755 3 Publications Verification	Src	Cancer
CH6953755 is a potent, orally active and selective *YES1* kinase (a member of the SRC family) inhibitor with an IC₅₀ of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo .

HY-112096

eCF506 3 Publications Verification NXP900	Src	Cancer
eCF506 (NXP900) is a highly potent and orally active *YES1/SRC* kinase inhibitor with an IC₅₀ of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer .

HY-10234A

Saracatinib difumarate Maximum Cited Publications 30 Publications Verification AZD0530 difumarate	Src	Cancer
Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .

HY-RS23413

Yes1 Rat Pre-designed siRNA Set A Yes; c-Yes; p61-Yes; p60c-Yes	Small Interfering RNA (siRNA)	Others
Yes1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Yes1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Yes1 Rat Pre-designed siRNA Set A Yes1 Rat Pre-designed siRNA Set A

HY-RS15922

YES1 Human Pre-designed siRNA Set A Yes; c-Yes; HsT441; P61-Yes	Small Interfering RNA (siRNA)	Others
YES1 Human Pre-designed siRNA Set A contains three designed siRNAs for YES1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

YES1 Human Pre-designed siRNA Set A YES1 Human Pre-designed siRNA Set A

HY-RS16970

Yes1 Mouse Pre-designed siRNA Set A Yes; p61-Yes	Small Interfering RNA (siRNA)	Others
Yes1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Yes1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Yes1 Mouse Pre-designed siRNA Set A Yes1 Mouse Pre-designed siRNA Set A

HY-15121S1

L-Theanine-13C2,15N2 L-Glutamic Acid γ-ethyl amide-¹³C₂,¹⁵N₂; Nγ-Ethyl-L-glutamine-¹³C₂,¹⁵N₂	DNA/RNA Synthesis	Others
L-Theanine-13C2,15N2yes ¹³C₂, ¹⁵N₂Tagged L-Theanine (HY-15121).

HY-169095

(S,R,S)-AHPC-Me-CO-C9-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-CO-C9-NH2yes E3Ligase ligand and PROTAC LinkerThe conjugate can be used to synthesize PROTACMolecules, such as MS41 (HY-169093).

HY-E70293

N-Acetylgalactosaminyltransferase 12 GALNT12	Endogenous Metabolite YAP	Cancer
N-Acetylgalactosaminyltransferase 12 (GALNT12) belongs to the uridine diphosphate N-acetylgalactosamine gene family and is involved in the biological processes of many diseases, such as tumor progression. N-Acetylgalactosaminyltransferase 12 is a potential biomarker for fibrosarcoma, and its high expression level is closely related to the yes1-associated transcriptional regulator (YAP1) signaling pathway .

HY-169087

MJBIA9836	Ligands for Target Protein for PROTAC	Cancer
MJBIA9836yes PROTACLigands for target proteins can be used to synthesize PROTACMolecules, such as MS41 (HY-169086).

HY-10395

PD173955 1 Publications Verification	Bcr-Abl Src	Cancer
PD173955 is an orally active inhibitor of Src (IC₅₀= 22 nM), *Yes, Abl, ATP* and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity .

HY-112096S

eCF506-d5 NXP900-d₅	Src Isotope-Labeled Compounds	Cancer
eCF506-d₅ (NXP900-d₅) is deuterated labeled eCF506 (HY-112096). eCF506 is a highly potent and orally active *YES1/SRC* kinase inhibitor with an IC₅₀ of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer .

HY-171217

TG-100435	Src Bcr-Abl Ephrin Receptor	Cancer
TG-100435 is a multitargeted, orally active protein tyrosine kinase inhibitor, with K_i of 13 to 64 nM for Src, Lyn, Abl, *Yes, Lck, and EphB4*. TG-100435 plays an important role in cancer research .

HY-125016

TT-10 1 Publications Verification TAZ-K	YAP	Cardiovascular Disease Cancer
TT-10 (TAZ-K) is an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity. TT-10 can be used for the research of heart diseases accompanied by cardiomyocyte loss .

HY-157083

mCMY020	YAP	Cancer
mCMY020 is a covalent inhibitor of TEAD. mCMY020 effectively reduces YAP (Yes-associated protein)-driven transcription and selectively slows the proliferation of Hippo-deficient cancer cells. mCMY020 can be used in cancer research .

HY-10234

Saracatinib Maximum Cited Publications 30 Publications Verification AZD0530	Src Autophagy	Cancer
Saracatinib (AZD0530) is a potent Src family inhibitor with IC₅₀s of 2.7 to 11 nM for c-Src, Lck, *c-YES, Lyn, Fyn, Fgr, and Blk*. Saracatinib shows high selectivity over other tyrosine kinases .

HY-30270

Mequinol p-Hydroxyanisole	HSP Estrogen Receptor/ERR	Endocrinology
Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .

HY-B0789

SU6656 10+ Cited Publications	Src FAK Akt	Cancer
SU6656 is a Src family kinases inhibitor with IC₅₀s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.

HY-10234AR

Saracatinib difumarate (Standard) AZD0530 difumarate (Standard)	Src Reference Standards	Cancer
Saracatinib (difumarate) (Standard) is the analytical standard of Saracatinib (difumarate). This product is intended for research and analytical applications. Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .

HY-10234R

Saracatinib (Standard) AZD0530 (Standard)	Reference Standards Src Autophagy	Cancer
Saracatinib (Standard) is the analytical standard of Saracatinib. This product is intended for research and analytical applications. Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .

HY-145373

BMS-986143	Btk	Inflammation/Immunology
BMS-986143 is an orally active, reversible BTK inhibitor with an IC₅₀ of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC₅₀s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases .

HY-30270R

Mequinol (Standard) p-Hydroxyanisole (Standard)	HSP Estrogen Receptor/ERR Reference Standards	Endocrinology
Mequinol (Standard) is the analytical standard of Mequinol. This product is intended for research and analytical applications. Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .

HY-10185

TG 100572 Hydrochloride 2 Publications Verification	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-13285

Ki16425 5+ Cited Publications Debio 0719	LPL Receptor YAP	Neurological Disease Cancer
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with K_is of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-10032

PF 477736 5 Publications Verification PF 00477736	Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, *Yes, Aurora-A, FGFR3, Flt3, and Ret* (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, *Yes*, respectively.

HY-13285R

Ki16425 (Standard)	LPL Receptor YAP	Neurological Disease Cancer
Ki16425 (Standard) is the analytical standard of Ki16425. This product is intended for research and analytical applications. Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-13561

AZM475271 M475271	Src Apoptosis	Cancer
AZM475271 (M475271) is an orally active and selective Src kinase inhibitor. AZM475271 inhibits phosphorylation of c-Src kinase, Lck, c-yes (IC₅₀s = 0.01, 0.03, 0.08 μM, respectively). AZM475271 induces apoptosis. AZM475271 reduces tumor cell proliferation and migration in vitro and in vivo, and reduces microvessel density (MVD). AZM475271 inhibits tumor growth and metastasis. AZM475271 sensitizes tumor cells to the cytotoxic effects of Gemcitabine (HY-17026) .

HY-136848

SM1-71	MAP3K Src FGFR Ribosomal S6 Kinase (RSK) LIM Kinase (LIMK)	Cancer
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a K_i of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, *YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1* and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines .

HY-158342

PROTAC TEAD degrader-1	PROTACs YAP	Cancer
PROTAC TEAD degrader-1 (Compound 27) is a PROTAC degrader for transcriptional enhanced associate domain (TEAD). PROTAC TEAD degrader-1 selectively degrades the Flag TEAD2 in a ubiquitin proteasome-dependent manner, with a DC₅₀ of 54.1 nM in 293T cells, inhibits proliferation of NF2-deficient NCI-H226 with an IC₅₀ of 0.21 μM, and regulates expressions of yes associated protein (YAP) target genes. (Pink: TEAD ligand (HY-158400); Black: linker (HY-W008474); Blue: E3 ligase ligand (HY-W087383))

Cat. No.	Product Name

HY-L022M

FDA-Approved Drug Library Mini	3,089 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,089 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

FDA-Approved Drug Library Mini

3,089 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,089 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-30270

Mequinol p-Hydroxyanisole	Structural Classification Monophenols Classification of Application Fields Source classification Mercurialis Other Diseases Phenols Euphorbiaceae Plants Disease Research Fields	HSP Estrogen Receptor/ERR
Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .

HY-30270R

Mequinol (Standard) p-Hydroxyanisole (Standard)	Structural Classification Monophenols Source classification Mercurialis Phenols Euphorbiaceae Plants	HSP Estrogen Receptor/ERR Reference Standards
Mequinol (Standard) is the analytical standard of Mequinol. This product is intended for research and analytical applications. Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .

Species:	Human (4)
Tag:	His (3) Avi (1) GST (2) Flag (1)
Source:	Sf9 insect cells (1) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73486

	YES1 Protein, Human (sf9, His-GST) 1 Publications Verification Tyrosine-protein kinase Yes; p61-Yes; Yes1; Yes	Human	Sf9 insect cells
	YES1 is a non-receptor protein tyrosine kinase that regulates processes such as cell growth, survival, apoptosis, and cell-cell adhesion. It is activated by RTKs (EGFR, PDGFR, CSF1R, FGFR) to phosphorylate downstream substrates. YES1 Protein, Human (sf9, His-GST) is the recombinant human-derived YES1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P702725

	YES1 Protein, Human (sf9, GST) Tyrosine-protein kinase Yes; p61-Yes; Yes1; Yes	Human	Sf9 insect cells
	YES1 is a non-receptor protein tyrosine kinase that regulates processes such as cell growth, survival, apoptosis, and cell-cell adhesion. It is activated by RTKs (EGFR, PDGFR, CSF1R, FGFR) to phosphorylate downstream substrates. YES1 Protein, Human (sf9, GST) is the recombinant human-derived YES1, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P704253

	YAP1 Protein, Human (His) Yes-associated protein 1; Protein yorkie homolog; Yes-associated protein YAP65 homolog; YAP65; YAP1	Human	E. coli

HY-P702727

	FYN Protein, Human (Biotinylated, sf9, His, Flag, Avi) FYN; FYN oncogene related to SRC, FGR, Yes; tyrosine-protein kinase Fyn; MGC45350; SLK; SYN; src-like kinase; proto-oncogene Syn; c-syn protooncogene; proto-oncogene c-Fyn; src/Yes-related novel; tyrosine kinase p59fyn(T); OKT3-induced calcium influx regulator; p59-FYN	Human	Sf9 insect cells
	FYN Protein, Human (Biotinylated, sf9, His, Flag, Avi) is the recombinant human-derived FYN, expressed by Sf9 insect cells , with Avi, His, Flag labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15121S1

L-Theanine-13C2,15N2
L-Theanine-13C2,15N2yes ¹³C₂, ¹⁵N₂Tagged L-Theanine (HY-15121).

HY-112096S

eCF506-d5

eCF506-d₅ (NXP900-d₅) is deuterated labeled eCF506 (HY-112096). eCF506 is a highly potent and orally active YES1/SRC kinase inhibitor with an IC₅₀ of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80747

	Lyn Antibody (YA707) LYN; JTK8; Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-Yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB	Human
	Lyn Antibody (YA707) is a non-conjugated and Mouse origined monoclonal antibody about 59 kDa, targeting to Lyn (1C8). It can be used for WB assays with tag free, in the background of Human.

HY-P80864

	Phospho-YAP1 (Ser127) Antibody (YA136) YAP1; YAP65; Yorkie homolog; 65 kDa Yes-associated protein; YAP65	WB, IHC-P	Human, Mouse, Rat
	Phospho-YAP1 (Ser127) Antibody (YA136) is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to Phospho-YAP1 (Ser127). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P82152

	Yes1 Antibody (YA1897) Yes1; Yes; Tyrosine-protein kinase Yes; Proto-oncogene c-Yes; p61-Yes	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	Yes1 Antibody (YA1897) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1897), targeting Yes1, with a predicted molecular weight of 61 kDa (observed band size: 61 kDa). Yes1 Antibody (YA1897) can be used for WB, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.

HY-P86138

	Yes1 Antibody (YA5830) Yes1; Yes; Tyrosine-protein kinase Yes; Proto-oncogene c-Yes; p61-Yes	WB, IHC-P, ICC/IF, IP, ELISA	Human

HY-P85116

	*c-Yes* Antibody (YA4808)** Yes1; Yes; Tyrosine-protein kinase Yes; Proto-oncogene c-Yes; p61-Yes	WB, ELISA	Human

HY-P85877

	LYN Antibody (YA5569) Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-Yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB, ICC/IF, ELISA	Human, Mouse, Rat,

HY-P85265

	Lyn Antibody (YA4957) LYN; JTK8; Tyrosine-protein kinase Lyn; Lck/Yes-related novel protein tyrosine kinase; V-Yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB, ELISA	Human

HY-P86386

	YAP Antibody (YA6078) YAP1; YAP65; Yorkie homolog; 65 kDa Yes-associated protein; YAP65	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat,

HY-P85545

	Fyn Antibody (YA5237) C syn protooncogene; Fyn; FYN oncogene related to SRC FGR Yes; FYN_HUMAN; MGC45350; OKT3 induced calcium influx regulator; P59 FYN; p59-Fyn; Protein tyrosine kinase fyn; Proto oncogene tyrosine protein kinase fyn; Proto-oncogene c-Fyn; Proto-oncogene Syn; Protooncogene Syn; SLK; Src like kinase; Src Yes related novel gene; Src-like kinase; Src/Yes related novel; Src/Yes related novel gene; SYN; Tyrosine kinase p59fyn T; Tyrosine kinase p59fyn; T; Tyrosine-protein kinase Fyn.	WB, ICC	Human, Monkey, Rat, Mouse

HY-P86167

	Phospho-YAP(Ser127) Antibody (YA5859) YAP1; YAP65; Yorkie homolog; 65 kDa Yes-associated protein; YAP65	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat